Loading
A phase 2 trial of Pembrolizumab and Dostarlimab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT05565378 by GlaxoSmithKline, with 351 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2026-11-09. Interventions recorded: Pembrolizumab, Dostarlimab, Belrestotug and Nelistotug.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dostarlimab, GSK, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/